Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
09 Março 2022 - 6:30PM
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
non-alcoholic steatohepatitis (NASH), announced today its
management team will participate in the 32nd Annual Oppenheimer
Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.
The fireside chat presentation will be webcast live and an
archived recording will be available for replay in the Investors
& Media section of the Madrigal website after the event.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
non-alcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s lead candidate, resmetirom, is a
once daily, oral, thyroid hormone receptor (THR)-β selective
agonist that is designed to target key underlying causes of NASH in
the liver. Resmetirom is currently being evaluated in two Phase 3
clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to
demonstrate multiple benefits in patients with NASH. For more
information, visit www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024